Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 HER2-expressing Cancers 1 Composite Lymphoma 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1

Interventions

Fulvestrant 125 Trastuzumab 114 Paclitaxel 113 Letrozole 108 pembrolizumab 79 pertuzumab 75 palbociclib 75 Capecitabine 72 Anastrozole 72 Cyclophosphamide 70 Carboplatin 67 abemaciclib 64 exemestane 63 Tamoxifen 63 ribociclib 60 trastuzumab deruxtecan 57 Surveys and Questionnaires 51 Specimen Handling 50 Radiotherapy 49 Docetaxel 49 Magnetic Resonance Spectroscopy 48 Blood Specimen Collection 40 olaparib 39 Standard of Care 36 Biopsy 33 sacituzumab govitecan 31 130-nm albumin-bound paclitaxel 31 Doxorubicin 30 Exercise 29 eribulin 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × ALX148 × 1 year × Clear all

NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡